利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

26 条记录 (耗时 0.034 秒)

    TOLEROGENIC POPULATIONS OF DENDRITIC CELLS
    7.
    发明申请
    TOLEROGENIC POPULATIONS OF DENDRITIC CELLS 有权
    致敏细胞的耐受性人群

    公开(公告)号：US20100080816A1

    公开(公告)日：2010-04-01

    申请号：US12566454

    申请日：2009-09-24

    申请人： Husein Hadeiba ,  Eugene C. Butcher

    发明人： Husein Hadeiba ,  Eugene C. Butcher

    IPC分类号： A61K39/00 ,  C12N5/071 ,  A61P37/02

    CPC分类号： A61K39/0008 ,  A61K2035/122 ,  A61K2039/5154 ,  C12N5/064

    摘要： Tolerogenic populations of dendritic cells are provided, where the dendritic cells are characterized by expression of select tissue-specific homing receptors including the chemokine receptors CCR9; or CMKLR1; or the integrin CD103. The dendritic cells may be conventional/myeloid or plasmacytoid dendritic cells. The cells may be isolated from lymphoid tissue, from blood, or from in vitro culture, e.g. bone marrow culture, etc. Methods are provided for their identification, isolation and targeting in immunotherapeutic interventions in suppressing inflammatory disorders including autoimmunity, transplantation responses and allergic diseases. In some embodiments dendritic cell populations are fixed to render them immunosuppressive, thus allowing the cells to be typed and banked for future use.

    摘要翻译： 提供树突状细胞的耐受性种群，其中树突细胞的特征在于选择性组织特异性归巢受体包括趋化因子受体CCR9的表达; 或CMKLR1; 或整合素CD103。 树突状细胞可以是常规/骨髓或浆细胞样树突状细胞。 细胞可以从淋巴组织，血液或体外培养中分离，例如， 骨髓培养等。提供了在免疫治疗干预中鉴别，分离和靶向抑制包括自身免疫，移植反应和过敏性疾病的炎性疾病的方法。 在一些实施方案中，树突状细胞群被固定以使其免疫抑制，从而允许细胞被分型和分组以备将来使用。

    Leukocyte homing modulation
    8.
    发明授权
    Leukocyte homing modulation 失效
    白细胞归巢调制

    公开(公告)号：US06387884B1

    公开(公告)日：2002-05-14

    申请号：US08336417

    申请日：1994-11-09

    申请人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    发明人： John L. Magnani ,  Eugene C. Butcher ,  Ellen L. Berg

    IPC分类号： A61K3170

    CPC分类号： C07H13/04 ,  A61K38/47 ,  A61K47/56 ,  C07K14/705 ,  C07K14/70564 ,  C07K16/30

    摘要： Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1−X[Fuc&agr;1−y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration.

    摘要翻译： 提供新的方法和组合物用于调节白细胞，特别是淋巴细胞的归巢，其中化合物与Neu5Ac2-3Galbeta1-X [Fucalpha1-y] GlcNAc交叉反应，其中x和y之一是三个，另一个是四个。 这些化合物可以施用于与炎症相关的宿主，以避免白细胞浸润的有害作用。

    Modulation of systemic memory T cell trafficking
    9.
    发明授权
    Modulation of systemic memory T cell trafficking 有权
    调节系统记忆T细胞运输

    公开(公告)号：US06245332B1

    公开(公告)日：2001-06-12

    申请号：US09232878

    申请日：1999-01-15

    申请人： Eugene C. Butcher ,  James J. Campbell ,  Lijun Wu ,  James B. Rottman

    发明人： Eugene C. Butcher ,  James J. Campbell ,  Lijun Wu ,  James B. Rottman

    IPC分类号： A61K3938

    CPC分类号： C07K16/2866 ,  A61K38/195 ,  A61K2039/505 ,  C07K16/24

    摘要： Methods are provided to specifically modulate the trafficking of systemic memory T cells, particularly CD4+ T cells, without affecting naive T cells or intestinal memory T cells. It is shown that systemic memory T cells, which are characterized as CD45Ra−, and integrin &agr;4&bgr;7−, express high levels of CCR4. Ligands of CCR4, such as TARC or MDC, act as an adhesion trigger, wherein upon CCR4 binding, these cells undergo integrin-dependent arrest to the appropriate vascular receptor(s). This arrest acts to localize the cells at the target site. The methods of the invention manipulate this triggering, and CCR4 mediated chemotaxis, to affect the localization of T cells in targeted tissues. In one embodiment of the invention, the active agent is a CCR4 agonist, that acts to enhance T cell localization. In an alternative embodiment, the agent is an antagonist that blocks CCR4 biological activity. An advantage of the invention is the selectivity for systemic memory T cells, without affecting native T cells or intestinal memory T cells.

    摘要翻译： 提供方法以特异性调节系统记忆T细胞，特别是CD4 + T细胞的运输，而不影响幼稚T细胞或肠内记忆T细胞。 其表现为CD45Rα和整合素α4β7-的全身记忆T细胞表达高水平的CCR4。 CCR4的配体如TARC或MDC作为粘附触发剂，其中在CCR4结合时，这些细胞经受整合素依赖性阻滞至合适的血管受体。 这次逮捕行动使细胞在目标地点本地化。 本发明的方法操纵这种触发和CCR4介导的趋化性，以影响T细胞在靶向组织中的定位。 在本发明的一个实施方案中，活性剂是用于增强T细胞定位的CCR4激动剂。 在替代实施方案中，所述试剂是阻断CCR4生物活性的拮抗剂。 本发明的优点是对全身记忆性T细胞的选择性，而不影响天然T细胞或肠内记忆T细胞。